First National Advisers LLC Increases Position in Thermo Fisher Scientific Inc. $TMO

First National Advisers LLC increased its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 121.0% in the fourth quarter, HoldingsChannel.com reports. The firm owned 6,646 shares of the medical research company’s stock after acquiring an additional 3,639 shares during the quarter. First National Advisers LLC’s holdings in Thermo Fisher Scientific were worth $3,851,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in the stock. Beacon Financial Strategies CORP acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $29,000. Olistico Wealth LLC acquired a new stake in Thermo Fisher Scientific in the 4th quarter valued at about $29,000. JPL Wealth Management LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at about $28,000. Cloud Capital Management LLC acquired a new stake in Thermo Fisher Scientific in the 3rd quarter valued at about $31,000. Finally, Thurston Springer Miller Herd & Titak Inc. grew its stake in Thermo Fisher Scientific by 195.7% in the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 68 shares of the medical research company’s stock valued at $39,000 after acquiring an additional 45 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insiders Place Their Bets

In related news, COO Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction on Monday, April 27th. The shares were sold at an average price of $462.66, for a total value of $185,064.00. Following the completion of the sale, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. The trade was a 1.57% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc N. Casper sold 5,000 shares of the business’s stock in a transaction on Wednesday, March 4th. The shares were sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the sale, the chief executive officer owned 123,925 shares of the company’s stock, valued at approximately $63,499,170. The trade was a 3.88% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on TMO. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Wednesday, April 8th. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research note on Friday. Morgan Stanley reaffirmed an “overweight” rating and set a $620.00 price target on shares of Thermo Fisher Scientific in a research note on Monday, April 27th. UBS Group reaffirmed a “neutral” rating and set a $615.00 price target on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Finally, Jefferies Financial Group raised shares of Thermo Fisher Scientific to a “strong-buy” rating in a research note on Friday, April 24th. Two research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Buy” and an average target price of $619.65.

Thermo Fisher Scientific Trading Down 2.8%

Shares of TMO stock opened at $452.14 on Tuesday. The stock has a market cap of $168.02 billion, a price-to-earnings ratio of 24.86, a price-to-earnings-growth ratio of 2.06 and a beta of 0.88. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. Thermo Fisher Scientific Inc. has a fifty-two week low of $385.46 and a fifty-two week high of $643.99. The firm’s 50 day moving average price is $491.19 and its two-hundred day moving average price is $545.39.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share for the quarter, beating analysts’ consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a net margin of 15.15% and a return on equity of 16.86%. The firm had revenue of $11.01 billion for the quarter, compared to analysts’ expectations of $10.86 billion. During the same period in the previous year, the company posted $5.15 earnings per share. Thermo Fisher Scientific’s revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 EPS for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date was Friday, March 13th. Thermo Fisher Scientific’s payout ratio is presently 10.34%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.